Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:KRRO NASDAQ:TECX NYSEAMERICAN:XTNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$14.85-1.1%$15.48$7.08▼$17.49$307.10M0.7790,421 shs55,223 shsKRROKorro Bio$31.23+1.5%$19.29$10.29▼$98.00$294.33M2.66128,853 shs73,380 shsTECXTectonic Therapeutic$17.17-3.1%$21.96$13.70▼$61.07$320.32M3.42291,693 shs153,439 shsXTNTXtant Medical$0.64+1.1%$0.62$0.33▼$0.78$83.14M-0.15119,956 shs129,453 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin0.00%-2.09%-4.09%+8.14%+25.08%KRROKorro Bio0.00%-7.29%+51.83%+130.76%-25.75%TECXTectonic Therapeutic0.00%+5.48%-24.63%-17.77%-1.50%XTNTXtant Medical0.00%+0.16%-0.11%+1.37%+9.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$14.85-1.1%$15.48$7.08▼$17.49$307.10M0.7790,421 shs55,223 shsKRROKorro Bio$31.23+1.5%$19.29$10.29▼$98.00$294.33M2.66128,853 shs73,380 shsTECXTectonic Therapeutic$17.17-3.1%$21.96$13.70▼$61.07$320.32M3.42291,693 shs153,439 shsXTNTXtant Medical$0.64+1.1%$0.62$0.33▼$0.78$83.14M-0.15119,956 shs129,453 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin0.00%-2.09%-4.09%+8.14%+25.08%KRROKorro Bio0.00%-7.29%+51.83%+130.76%-25.75%TECXTectonic Therapeutic0.00%+5.48%-24.63%-17.77%-1.50%XTNTXtant Medical0.00%+0.16%-0.11%+1.37%+9.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.50Reduce$12.00-19.19% DownsideKRROKorro Bio 3.29Buy$86.83178.08% UpsideTECXTectonic Therapeutic 3.14Buy$80.29367.59% UpsideXTNTXtant Medical 3.00Buy$1.50135.11% UpsideCurrent Analyst Ratings BreakdownLatest XTNT, KRRO, AMRN, and TECX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025TECXTectonic TherapeuticOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.008/25/2025AMRNAmarinZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/13/2025KRROKorro BioRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetStrong-Buy$153.00 ➝ $147.008/13/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $90.007/24/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.007/21/2025TECXTectonic TherapeuticTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$64.006/25/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$7.00 ➝ $12.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M1.34N/AN/A$23.62 per share0.63KRROKorro Bio$2.27M129.17N/AN/A$17.12 per share1.82TECXTectonic TherapeuticN/AN/AN/AN/A$9.54 per shareN/AXTNTXtant Medical$117.27M0.71N/AN/A$0.31 per share2.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%10/29/2025 (Estimated)KRROKorro Bio-$83.58M-$9.75N/AN/AN/AN/A-61.51%-42.87%11/11/2025 (Estimated)TECXTectonic Therapeutic-$57.98M-$4.04N/AN/AN/AN/A-30.13%-28.33%11/6/2025 (Estimated)XTNTXtant Medical-$16.45M-$0.13N/A∞N/A-3.59%-10.12%-4.67%11/12/2025 (Estimated)Latest XTNT, KRRO, AMRN, and TECX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025KRROKorro Bio-$2.54-$2.74-$0.20-$2.74$0.41 million$1.46 million8/7/2025Q2 2025TECXTectonic Therapeutic-$0.98-$1.07-$0.09-$1.07N/AN/A7/30/2025Q2 2025AMRNAmarin-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/AXTNTXtant MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.262.34KRROKorro BioN/A5.985.98TECXTectonic TherapeuticN/A25.6025.60XTNTXtant Medical0.462.471.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%KRROKorro Bio13.18%TECXTectonic Therapeutic62.63%XTNTXtant Medical69.33%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%KRROKorro Bio4.60%TECXTectonic Therapeutic9.20%XTNTXtant Medical9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.68 million20.28 millionOptionableKRROKorro Bio709.39 million8.96 millionNo DataTECXTectonic Therapeutic12018.71 million16.99 millionN/AXTNTXtant Medical120130.32 million117.68 millionNot OptionableXTNT, KRRO, AMRN, and TECX HeadlinesRecent News About These CompaniesXtant Medical (NYSEAMERICAN:XTNT) Shares Pass Above 200-Day Moving Average - Should You Sell?September 8, 2025 | marketbeat.comXtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | prnewswire.comXtant Medical (NYSEAMERICAN:XTNT) Shares Pass Above 200-Day Moving Average - Here's WhyAugust 31, 2025 | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Stock Passes Above Two Hundred Day Moving Average - Should You Sell?August 23, 2025 | marketbeat.comEarnings To Watch: Xtant Medical Holdings Inc (XTNT) Reports Q2 2025 ResultAugust 13, 2025 | finance.yahoo.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comXtant Medical Reports Strong Q2 2025 ResultsAugust 13, 2025 | msn.comXtant Medical Holdings, Inc.: Xtant Medical Reports Second Quarter 2025 Financial ResultsAugust 12, 2025 | finanznachrichten.deXtant Medical Holdings, Inc. (XTNT) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comXtant Medical Reports Second Quarter 2025 Financial ResultsAugust 12, 2025 | prnewswire.comEarnings Preview For Xtant Medical HldgsAugust 11, 2025 | benzinga.comXtant Medical to Attend the CG 45th Annual Growth ConferenceAugust 6, 2025 | prnewswire.comXtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025August 5, 2025 | prnewswire.comXtant Medical Partners With B2i Digital to Educate Investors on Its Orthobiologics Innovation and Market OpportunityJuly 29, 2025 | finance.yahoo.comXtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion SpineJuly 8, 2025 | prnewswire.comXtant Medical Holdings Inc Share Price (XTNT.US)June 4, 2025 | lse.co.ukXtant Medical Announces the Launch of OsteoFactor Pro™May 28, 2025 | prnewswire.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comXtant Medical Holdings, Inc.: Xtant Medical Reports First Quarter 2025 Financial ResultsMay 13, 2025 | finanznachrichten.deXtant Medical Holdings Inc (XTNT) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...May 13, 2025 | finance.yahoo.comXtant Medical outlines 8–11% revenue growth target for 2025 as company completes vertical integration and launches new productsMay 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTNT, KRRO, AMRN, and TECX Company DescriptionsAmarin NASDAQ:AMRN$14.85 -0.16 (-1.07%) As of 02:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Korro Bio NASDAQ:KRRO$31.23 +0.47 (+1.51%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Tectonic Therapeutic NASDAQ:TECX$17.17 -0.55 (-3.10%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.Xtant Medical NYSEAMERICAN:XTNT$0.64 +0.01 (+1.11%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
